Backed by science and real results, Swiss Medica is leading the way in regenerative stem cell therapies with personalized treatments that go beyond symptom management to restore function and quality of life.
Neurodegenerative and neurodevelopmental disorders affect millions worldwide—silently progressing, gradually stripping individuals of movement, memory, speech, as well as independence. These conditions, including multiple sclerosis (MS), Parkinson’s disease, Alzheimer’s, and Autism Spectrum Disorder, are among the most challenging to treat.
In 2021, over 3 billion people were living with neurological conditions—and with an aging population, this number is rising fast. Up to 15% of people over the age of 80 develop neurodegenerative diseases, and the global burden is expected to double, or even triple, in the next 20 years.
The challenge? Neurons rarely regenerate. By the time symptoms appear, over half may already be lost. Most treatments only manage symptoms—like in Parkinson’s disease, where medications reduce tremors but don’t stop neuron death.
This is where regenerative medicine begins to shift the narrative.
By using stem cell therapy, scientists and clinicians aim not only to slow disease progression—but to restore lost functions and improve quality of life. In MS, for example, stem cells help reduce inflammation, support neuron survival, and even stimulate the repair of myelin, the protective layer around nerve fibers. Patients report increased energy, better motor control, fewer muscle spasms, and sharper cognitive function.
Similar regenerative approaches are being explored for stroke recovery. While traditional medicine can stabilize a patient, it rarely restores lost abilities. With stem cell treatments, ischemic stroke patients have shown improvement in motor function.
Swiss Medica’s Stem Cell Therapy and Research
Swiss Medica, a leading stem cell clinic, is at the forefront of this revolution in care. With over a decade of experience in stem cell therapy, Swiss Medica provides individualized treatment programs for complex neurological conditions.
For patients with multiple sclerosis, Swiss Medica provides personalized options, including stem cell treatments for MS, using stem cells derived from bone marrow, the umbilical cord or the placenta, complemented by therapies such as plasmapheresis and intracellular metabolic therapy.
In the field of stem cells for autism, Swiss Medica conducted a study, where up to 90% showed improvements in both communication and behavior after receiving mesenchymal stem cells and exosome therapy. Patients’ attention span also improved in over half of the group who received treatment.
Behind each treatment is a commitment to research and safety. The clinic’s dedicated research branch continues to explore new protocols and cellular therapies that meet the highest ethical and medical standards.
And while stem cell cost can vary depending on the condition and number of cells used, the clinic maintains transparency and works with patients to create personalized programs aligned with their medical and financial needs.
Swiss Medica is helping to shape a new approach to patient care, where regenerative medicine supports recovery and functional improvement, turning what once seemed like future possibilities into present-day realities.
Find out more about Global Health campaign
